Dernières nouvelles pour Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Nurix Therapeutics Inc

Analysts' ratings for Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $20.25, a high estimate of $25.00, and a low estimate of $17.00. This current average has decreased by 12.9% from the previous average price target of $23.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1732712425_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Kohl's by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kohl's. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kohl's compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Kohl's's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Kohl's's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KSS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Kohl's analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Kohl's</h2>
Kohl's operates about 1,176 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 26% of its 2023 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
<h3>Understanding the Numbers: Kohl's's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Kohl's's financials over 3 months reveals challenges. As of 31 July, 2024, the company experienced a decline of approximately -4.18% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.77%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.73%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.46%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Kohl's's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.95.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 4 Analyst Ratings Have To Say About Kohl's

Sony Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) short percent of float has fallen 11.11% since its last report. The company recently reported that it has 9.50 million shares sold short, which is 0.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sony Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732712424_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sony Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sony Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sony Gr's peer group average for short interest as a percentage of float is 11.01%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Sony Group Corporation American Depositary Shares

SONY

How Is The Market Feeling About Sony Gr?

Jim Cramer, the outspoken host of CNBC's Mad Money, has publicly voiced his frustration over the backlash he receives for <a href="https://www.benzinga.com/markets/equities/24/11/42181201/jim-cramers-apple-endorsement-sparks-inverse-cramer-backlash-as-social-media-users-mock-his-own-it-advice">his market predictions</a>.
What Happened: <a href="https://www.youtube.com/watch?v=iyZS4EDFh2k">Speaking</a> candidly during a segment on Monday, Cramer acknowledged the intense scrutiny and personal attacks he faces, suggesting the weight of the criticism is taking a toll.
"I cannot take so much abuse," Cramer admitted during the broadcast, reflecting on the relentless criticism from both social media users and market observers. 
Known for his high-energy stock recommendations, Cramer has often found himself at the center of heated debates, with critics questioning the accuracy and impact of his financial advice.
In recent months, Cramer has faced heightened scrutiny as volatile markets have magnified the stakes of his calls. 
Responding to critics, he noted that the discourse has shifted beyond professional disagreements, adding, "The attacks have become personal, and it's no longer about the stocks—it's about tearing me down."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42099670/core-fusion-upgrade-introduces-dual-staking-and-liquid-bitcoin-staking">Core Fusion Upgrade Introduces Dual Staking And Liquid Bitcoin Staking</a>
Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price dropped by 2% on the same day Cramer advocated for cryptocurrencies as a part of every investor&#8217;s portfolio.
A statement on X on Monday to own Apple Inc. stock drew ridicule from the online community, with commentators describing Cramer as &#8220;financial QVC&#8221; and &#8220;the ultimate inverse indicator.&#8221;
Cramer, often the subject of memes due to the perceived inaccuracy of his market predictions, has faced criticism for his advice. 
At one point, a <a href="https://www.benzinga.com/etfs/specialty-etfs/24/01/36793492/exclusive-inverse-cramer-etf-shuts-down-how-the-magnificent-7-stocks-factor-in-and-a-broken-c#:~:text=An%20ETF%20that%20generated%20headlines,shut%20the%20fund%20was%20made.">short-lived exchange-traded fund</a> (ETF) was even created to profit by betting against his recommendations.
During the Nov. 26 episode of CNBC's Mad Money, Cramer argued that <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42205579/jim-cramer-says-bitcoin-and-ethereum-deserve-a-spot-in-your-portfolio-as-hedge-against-rising-us-debt-ive-liked-crypto-for-a-very-long-time">owning cryptocurrencies could act as a hedge</a> against the U.S.'s growing deficit, which has now surpassed $36 trillion.
"I think Bitcoin, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), and maybe even some other cryptocurrencies deserve a spot in your portfolio," Cramer stated. "Maybe one day, if the deficit gets under control, I'll change my tune."
Cramer&#8217;s call echoes the thesis by JPMorgan analysts, who called Bitcoin the &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41170398/bitcoin-gold-are-the-debasement-trade-in-uncertain-times-jpmorgan">debasement trade</a>&#8221; in light of the rising government debt burden.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42096519/bitcoin-to-reach-190000-this-cycle-michael-terpin-of-transform-group-says">Bitcoin To Reach $190,000 This Cycle, Michael Terpin Of Transform Ventures Says</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

Jim Cramer 'Cannot Take So Much Abuse' After Drawing Ridicule For Bitcoin, Apple Calls — But He's Not The Only One Touting BTC

Honeywell Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HON#NYSE">HON</a>) short percent of float has risen 16.26% since its last report. The company recently reported that it has 9.28 million shares sold short, which is 1.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Honeywell Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732712418_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Honeywell Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Honeywell Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Honeywell Intl's peer group average for short interest as a percentage of float is 7.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Honeywell Intl's Recent Short Interest

Fidelity National Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) short percent of float has fallen 31.39% since its last report. The company recently reported that it has 2.08 million shares sold short, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fidelity National Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732712413_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fidelity National Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fidelity National Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fidelity National Finl's peer group average for short interest as a percentage of float is 1.76%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Fidelity National Finl?

Baird analyst Michael Bellisario initiates coverage on Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Outperform rating and announces Price Target of $5850.

Price Target

Initiation

BKNG

Baird Initiates Coverage On Booking Holdings with Outperform Rating, Announces Price Target of $5850

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and raises the price target from $27 to $40.

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Raises Price Target to $40

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and lowers the price target from $23 to $17.

Telsey Advisory Group Maintains Market Perform on Kohl's, Lowers Price Target to $17

On Tuesday, PTC Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42201952/ptc-therapeutics-announces-topline-results-of-cardinals-trial-of-utreloxastat-in-als-patients" rel="noreferrer noopener">lateral sclerosis patients</a>.
The study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41984686/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with-direct-administration-in-brain" rel="noreferrer noopener">FDA Grants Conditional Approval For PTC Therapeutics&#8217; Gene Therapy As First Ever With Direct Administration In Brain</a>
While modest numerical benefit was recorded on the primary endpoint, and a favorable clinical effect was correlated with lowering plasma neurofilament light chain (NfL), a biomarker of neuronal damage, statistical significance was not achieved (p= 0.52). In addition, significance was not achieved on the secondary efficacy endpoints.
Amyotrophic lateral sclerosis (ALS), sometimes referred to as motor neuron disease or&nbsp;Lou Gehrig&#8217;s&nbsp;disease, is a rare neurodegenerative disease that affects motor neurons in the brain and spinal cord.
Utreloxastat was demonstrated to be safe and well-tolerated in the CardinALS trial. However, further development is not planned due to the lack of efficacy and biomarker signal.
William Blair notes that while the CardinALS trial results were disappointing, the program was not a major factor in its investment thesis. As a result, ending the program does not affect the firm&#8217;s Outperform <a target="_blank" href="https://www.benzinga.com/quote/PTCT/analyst-ratings" rel="noreferrer noopener">rating on the stock</a>.
The analyst highlights the potential approval and launch of sepiapterin as a key growth driver over the next year, particularly in treating Phenylketonuria (PKU). William Blair believes the market is undervaluing this opportunity, with a PDUFA decision expected in July.
The analyst also points to growing investor interest in the company&#8217;s Huntington&#8217;s disease program. Given the strong commercial prospects of this small-molecule therapy, positive discussions with regulators about an accelerated approval pathway for PTC-518 could significantly boost the stock. A Type C meeting with the FDA is planned for the fourth quarter to discuss the regulatory pathway.
Additionally, the company aims to file a U.S. marketing application for vatiquinone in Friedreich&#8217;s ataxia (FA) by late 2024. William Blair expects approval based on the drug&#8217;s clinical data and the FDA&#8217;s recent neurology approvals, especially as no treatments exist for pediatric FA patients.
On Wednesday, PTC Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42210840/ptc-therapeutics-enters-into-agreement-to-sell-priority-review-voucher-for-150-million" rel="noreferrer noopener">for $150 million</a>.
PTC was granted the voucher along with the FDA approval of Kebilidi (eladocagene exuparvovec-tneq) for children and adults <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41984686/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with-direct-administration-in-brain" rel="noreferrer noopener">with AADC deficiency</a>.
Price Action: PTCT stock is down 1.98% at $45.10 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42210794/frontlines-strong-q3-revenue-growth-offset-by-seasonal-tanker-headwinds-and-geopolitical-challenges" target="_blank" rel="noreferrer noopener">Frontline Posts Mixed Q3 Amid Seasonal Tanker Headwinds And Geopolitical Challenges: Details</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Biotech

Equities

Health Care

Reiteration

General

PTCT

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Guggenheim analyst Shahriar Pourreza maintains New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) with a Neutral and raises the price target from $46 to $49.

Guggenheim Maintains Neutral on New Jersey Resources, Raises Price Target to $49

Northland Capital Markets analyst Mike Grondahl maintains MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) with a Outperform and raises the price target from $80 to $100.

Northland Capital Markets Maintains Outperform on MoneyLion, Raises Price Target to $100

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and lowers the price target from $21 to $18.

Telsey Advisory Group Maintains Market Perform on Guess, Lowers Price Target to $18

Guggenheim analyst Robert Drbul maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Buy and lowers the price target from $26 to $25.

Guggenheim Maintains Buy on Kohl's, Lowers Price Target to $25

Telsey Advisory Group analyst Dana Telsey maintains Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) with a Market Perform and raises the price target from $24 to $26.

Telsey Advisory Group Maintains Market Perform on Nordstrom, Raises Price Target to $26

Northland Capital Markets analyst Gus Richard reiterates Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Outperform and raises the price target from $75 to $95.

AMBA

Northland Capital Markets Reiterates Outperform on Ambarella, Raises Price Target to $95

During President-elect Trump's first term, U.S. scrap metal recyclers benefited significantly from the administration's trade policies – tariffs materially increased the cost of imported steel, leading to significant increases in the prices of domestic recycled metals. As&nbsp;Sims Limited's recent $220 million acquisition of Baltimore Steel(1) demonstrated, industry leaders place significant value in scrap metal operators with proprietary supply channels, seasoned leadership, and established operations.

GWAV

Greenwave Technology Solutions Says That It Expects Tariffs On U.S. Steel Imports Will Drive The Company's Revenue Growth And Margin Expansion Throughout Fiscal Year 2025

Telsey Advisory Group analyst Dana Telsey maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Outperform and raises the price target from $310 to $320.

BURL

Telsey Advisory Group Maintains Outperform on Burlington Stores, Raises Price Target to $320

FY Financial 2024 Update(1):
Preliminary unaudited FY 2024 revenue is estimated at US$44.6 million(1)
Margins for FY2024 is estimated at approximately 31%
Expected operating profit and improved Adjusted EBITDA(2) for FY2024
FY Financial 2025 Preview:
The Company anticipates strong growth into FY2025 with estimated revenues to exceed $60 million driven by renewed demand from the Company's largest end users of material handling batteries.
This guidance was prepared by taking into account the Company's existing purchase orders, along with anticipated pipeline from its key end users and OEM customers. This guidance also takes into consideration a percentage of anticipated revenue that potentially may be deferred to FY 2026.

ELVA

Electrovaya Expects $45M FY24 Revenue ($45.06M Est.) With 31% Margin; Anticipates $60M+ FY25 Revenues Amid Jamestown Expansion And New Markets

Northland Capital Markets analyst Nehal Chokshi reiterates Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Market Perform and raises the price target from $74 to $77.

NTNX

Northland Capital Markets Reiterates Market Perform on Nutanix, Raises Price Target to $77

Guggenheim analyst Seamus Fernandez maintains Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy and raises the price target from $95 to $110.

APGE

Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $110

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

Immunocore Holdings plc - American Depositary Shares

Immunocore Hldgs

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

MannKind

Myriad Genetics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Nurix Therapeutics

Actualités

Dernières nouvelles pour Nurix Therapeutics (NASDAQ:NRIX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL